Irinotecan Liposome
Phase 2Small molecule
Institut de Recherches Internationales ServierIrinotecan Liposome is one of 279 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.
9
Indications
21
Total Trials
16
Active Trials
278
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Irinotecan Liposome
Institut de Recherches Internationales ServierPhase 2
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer3 trials
Metastatic Colorectal Cancer3 trials
Esophageal Squamous Cell Carcinoma1 trial
11 more indications
Adenocarcinoma1 trial
Capecitabine1 trial
Efficacy and Safety1 trial
Recurrent or Metastatic NPC1 trial
Colorectal Cancer1 trial
Breast Cancer1 trial
Nasopharyngeal Carcinoma1 trial
Stomach Neoplasms1 trial
Biliary Tract Cancer1 trial
A Prospective, Single-Arm, Exploratory Clinical Study of Liposomal Irinotecan (II) Plus 5-Fluorouracil/Leucovorin and Sintilimab With Sequential Stereotactic Body Radiation Therapy as First-Line Treatment for Locally Advanced Biliary Tract Cancer
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT07797816·31 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Irinotecan Liposome. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details